MedTrace Logo

Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT03505944 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2021-10-13

No results posted yet for this study

Summary

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

Conditions

  • Relapsed Non Hodgkin Lymphoma

Interventions

DRUG

Venetoclax

venetoclax + lenalidomide + rituximab

Sponsors & Collaborators

  • Nordic Lymphoma Group

    lead NETWORK

Principal Investigators

  • Mats Jerkeman · Skane University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • Denmark
  • Finland
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03505944 on ClinicalTrials.gov